JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP) Files An 8-K Results of Operations and Financial Condition
Item2.02.
| Results of Operation and Financial Condition |
On November 15, 2016, Juniper Pharmaceuticals, Inc. (the
Company), issued a press release announcing the financial results
for the three-month period ending September30, 2016, entitled
Juniper Pharmaceuticals Reports Third Quarter 2016 Financial
Results (the Press Release). A copy of the Press Release is
furnished as Exhibit 99.1 hereto and is incorporated herein by
reference.
The information contained in this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for the
purposes of Section18 of the United State Securities Exchange Act
of 1934, as amended, or otherwise subject to the liability of
Section18. Furthermore, the information shall not be deemed
incorporated by reference into any registration statement or any
other filing under the United States Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
references in such filings.
Item9.01. |
Financial Statements and Exhibits |
(d) |
Exhibits |
|
|
|
|
| 99.1 |
Press Release dated November 15, 2016, entitled Juniper Pharmaceuticals Reports Third Quarter 2016 Financial Results, furnished herewith |
About JUNIPER PHARMACEUTICALS, INC. (NASDAQ:JNP)
